Compare FRAF & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | ENTA |
|---|---|---|
| Founded | 1906 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.9M | 303.8M |
| IPO Year | 1995 | 2012 |
| Metric | FRAF | ENTA |
|---|---|---|
| Price | $67.94 | $8.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.83 |
| AVG Volume (30 Days) | 43.4K | ★ 261.5K |
| Earning Date | 10-27-2026 | 11-16-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 88.84 | 38.80 |
| EPS | ★ 4.84 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | $6.58 | $34.79 |
| P/E Ratio | $14.08 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $45.16 | $8.61 |
| 52 Week High | $73.69 | $17.15 |
| Indicator | FRAF | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 28.55 |
| Support Level | $60.62 | N/A |
| Resistance Level | $73.69 | $13.94 |
| Average True Range (ATR) | 1.95 | 0.84 |
| MACD | -0.40 | -0.20 |
| Stochastic Oscillator | 6.27 | 0.07 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking, and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals, and governmental entities, which include accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.